AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel lead compound identified via virtual screening validated as a selective kappa-opioid receptor agonist

Summary

Pain relief and management can be achieved via targeted binding of opioid receptors by agonists. While currently available opioid receptor agonists effectively reduce pain, they can also cause addiction. Kappa-opioid receptors are a subtype that can be targeted to reduce pain without this side effect. Columbia scientists identified a selective kappa-opioid receptor agonist via high throughput in silico screening and validated it via BRET-based assays.

Technology Benefits

Effective pain treatment with minimal side effectsSelective at kappa-opioid receptorProvides scaffold for development of new molecules with G protein bias, resulting in better analgesics with less adverse effects Patent Information:Patent Pending (WO/2014/127256)Tech Ventures Reference: IR CU13090, CU12282

Technology Application

Pain treatment without side effects such as addiction and dysphoriaChemical tool to study the endogenous opioid system

Detailed Technology Description

None

Country/Region

USA

For more information, please click Here